Biodesix Exec and Former Exact Sciences Commercial Leader Adds Marketing Depth to Board Denver, CO – May 5, 2022 – HepQuant, LLC, a Denver, Colorado-based company with a unique, patented and... read more →
HepQuant Names Pharma and Medical Device Veteran Ally Xu Director of Regulatory and Quality Affairs DENVER (Feb. 1, 2022) — HepQuant, LLC, a Denver, Colorado-based company with a unique, patented and... read more →
HepQuant Results Presented while Attending the 72nd AASLD Annual Meeting and AHA 2021 Annual Meeting DENVER (November 16th, 2021) — HepQuant, LLC, a Denver, Colorado-based company with a unique, patented and patent-pending... read more →
Perspectum and HepQuant Announce Partnership to Bring a More Complete Picture of Liver Health Partnership Combines Imaging and Functional Assessment for Clinical Research San Francisco, CA and Denver, CO –... read more →
HepQuant’s Greg Everson, MD, to Speak at AASLD/FDA Conference on Drug-Induced Liver Injury (DILI) DENVER (April 14th, 2021) — HepQuant, LLC, a Denver, Colorado-based company with a unique, patented and patent-pending... read more →
HepQuant Promotes Sean Bundy, RAC, to Chief Operating Officer Denver, CO – June 10, 2020 – HepQuant, LLC, a Greenwood Village, Colo.-based company with a unique, patented and patent-pending technology... read more →
HepQuant to Offer Mobile and Remote Test Administration in Clinical Trials via CVS Health’s Coram Clinical Trials DENVER (February 18th, 2020) — HepQuant, LLC, a Greenwood Village, Colorado-based company with... read more →
HepQuant to Present at Biotech Showcase™ 2020 San Francisco Event to be held January 13–15th DENVER (Jan. 10, 2020) — HepQuant, LLC, a Greenwood Village, Colorado-based company with a unique, patented... read more →
HepQuant’s Disease Severity Index (DSI) Demonstrates Hepatic Functional Improvement in High Percentage of NASH Patients Treated with Obeticholic Acid: Results from INTERCEPT 747-117 The First HepQuant SHUNT™ Data From An... read more →